Skip to main content
Top
Published in: Cancer Chemotherapy and Pharmacology 1/2006

01-01-2006 | Original Article

Preliminary safety evaluation of the putative cancer chemopreventive agent tricin, a naturally occurring flavone

Authors: Richard D. Verschoyle, Peter Greaves, Hong Cai, Arndt Borkhardt, Massimo Broggini, Maurizio D’Incalci, Ed Riccio, Rupa Doppalapudi, Izet M. Kapetanovic, William P. Steward, Andreas J. Gescher

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2006

Login to get access

Abstract

Purpose: Naturally occurring flavonoids such as quercetin and genistein possess cancer chemopreventive properties in experimental models. However, adverse effects such as their mutagenicity confound their potential clinical usefulness. Furthermore in leukaemia cells some flavonoids cleave the breakpoint cluster region of the mixed lineage leukaemia (MLL) gene as a consequence of inhibition of topoisomerase II. The choice of flavonoids to be developed as cancer chemopreventive agents depends crucially on their safety. Here, we explored safety aspects of the novel flavone tricin, a constituent of rice bran and other grass species, which has recently been found to interfere with murine gastrointestinal carcinogenesis. Methods: Evidence of pathological or morphological changes in liver, lung, heart, spleen, kidney, adrenal gland, pancreas or thymus tissues was studied in mice which received tricin, genistein or quercetin 1,000 mg/kg daily by the oral route on five consecutive days. The ability of tricin (50 μM) to cleave the MLL gene was studied in human leukaemia cells by Southern blotting, and its effect on human topoisomerase II activity was investigated in incubations with supercoiled DNA. The mutagenicity of tricin was assessed in the Salmonella/Escherichia coli assay, and its clastogenicity was adjudged by chromosomal aberrations in Chinese hamster ovary cells and occurrence of micronuclei in bone marrow erythrocytes in Swiss-Webster mice. Results: Neither tricin, quercetin, or genistein caused pathological or morphological changes in any of the murine tissues studied. Tricin (50 μM) failed to cause MLL gene breakage, and it inhibited topoisomerase II only at 500 μM, but not at 10, 50 or 100 μM. Tricin lacked genotoxic properties in the systems studied here. Conclusion: The results tentatively suggest that tricin may be considered safe enough for clinical development as a cancer chemopreventive agent.
Literature
2.
go back to reference Verma AK, Johnson JA, Gould MN, Tanner MA (1988) Inhibition of 7,12-dimethylbenz[a]anthracene- and N-nitrosomethylurea-induced rat mammary cancer by dietary flavonol quercetin. Cancer Res 48:5754–5758PubMed Verma AK, Johnson JA, Gould MN, Tanner MA (1988) Inhibition of 7,12-dimethylbenz[a]anthracene- and N-nitrosomethylurea-induced rat mammary cancer by dietary flavonol quercetin. Cancer Res 48:5754–5758PubMed
3.
go back to reference Lamartiniere CA, Moore JB, Brown NM, Thompson R, Hardin MJ, Barnes S (1995) Genistein suppresses mammary cancer in rats. Carcinogenesis 16:2833–2840PubMedCrossRef Lamartiniere CA, Moore JB, Brown NM, Thompson R, Hardin MJ, Barnes S (1995) Genistein suppresses mammary cancer in rats. Carcinogenesis 16:2833–2840PubMedCrossRef
4.
go back to reference Murrill WB, Brown NM, Zhang J-X, Manzolillo PA, Barnes S, Lamartiniere CA (1996) Prepubertal genistein exposure suppresses mammary cancer and enhances gland differentiation in rats. Carcinogenesis 17:1451–1457PubMedCrossRef Murrill WB, Brown NM, Zhang J-X, Manzolillo PA, Barnes S, Lamartiniere CA (1996) Prepubertal genistein exposure suppresses mammary cancer and enhances gland differentiation in rats. Carcinogenesis 17:1451–1457PubMedCrossRef
5.
go back to reference Iwashina T (2000) The structure and distribution of the flavonoids in plants. J Plant Res 113:287–299CrossRef Iwashina T (2000) The structure and distribution of the flavonoids in plants. J Plant Res 113:287–299CrossRef
6.
go back to reference Seino Y, Nagao M, Yahagi T, Sugimura T, Yasuda T, Nishimura S (1978) Identification of a mutagenic substance in a spice, sumac, as quercetin. Mutat Res 58:225–229CrossRefPubMed Seino Y, Nagao M, Yahagi T, Sugimura T, Yasuda T, Nishimura S (1978) Identification of a mutagenic substance in a spice, sumac, as quercetin. Mutat Res 58:225–229CrossRefPubMed
7.
go back to reference Nakayasu M, Sakamoto H, Terada M, Nagao M, Sugimura T (1986) Mutagenicity of quercetin in Chinese hamster lung cells in culture. Mutat Res 174:79–83CrossRefPubMed Nakayasu M, Sakamoto H, Terada M, Nagao M, Sugimura T (1986) Mutagenicity of quercetin in Chinese hamster lung cells in culture. Mutat Res 174:79–83CrossRefPubMed
8.
go back to reference Rao CV, Wang CX, Simi B, Lubet R, Kelloff G, Steele V, Reddy BS (1997) Enhancement of experimental colon cancer by genistein. Cancer Res 57:3717–3722PubMed Rao CV, Wang CX, Simi B, Lubet R, Kelloff G, Steele V, Reddy BS (1997) Enhancement of experimental colon cancer by genistein. Cancer Res 57:3717–3722PubMed
9.
go back to reference Strick R, Strissel PL, Borgers S, Smith SL, Rowley JD (2000) Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia. Proc Natl Acad Sci USA 97:4790–4795CrossRefPubMed Strick R, Strissel PL, Borgers S, Smith SL, Rowley JD (2000) Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia. Proc Natl Acad Sci USA 97:4790–4795CrossRefPubMed
10.
go back to reference Hudson EA, Dinh PA, Kokubun T, Simmonds MSJ, Gescher A (2000) Characterization of potentially chemopreventive phenols in extracts of brown rice that inhibit the growth of human breast and colon cancer cells. Cancer Epidemiol Biomarkers Prev 9:1163–1170PubMed Hudson EA, Dinh PA, Kokubun T, Simmonds MSJ, Gescher A (2000) Characterization of potentially chemopreventive phenols in extracts of brown rice that inhibit the growth of human breast and colon cancer cells. Cancer Epidemiol Biomarkers Prev 9:1163–1170PubMed
11.
go back to reference Cai H, Verschoyle RD, Tunstall RG, Al-Fayez M, Platton S, Steward WP, Gescher AJ (2005) Inhibition of intestinal carcinogenesis in mice by rice bran or its constituent flavone tricin, a potent cyclooxygenase inhibitor. (Submitted) Cai H, Verschoyle RD, Tunstall RG, Al-Fayez M, Platton S, Steward WP, Gescher AJ (2005) Inhibition of intestinal carcinogenesis in mice by rice bran or its constituent flavone tricin, a potent cyclooxygenase inhibitor. (Submitted)
12.
go back to reference Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell DR, Raymond R, Stables R, Stephens T, Wallace J, Navaratnam V (1998) United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer 77:1–10 Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell DR, Raymond R, Stables R, Stephens T, Wallace J, Navaratnam V (1998) United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer 77:1–10
13.
go back to reference Cai H, Steward WP, Gescher AJ (2005) Determination of the putative cancer chemopreventive flavone tricin in plasma and tissues of mice by HPLC with UV-visible detection. Biomed Chromatogr (in press) Cai H, Steward WP, Gescher AJ (2005) Determination of the putative cancer chemopreventive flavone tricin in plasma and tissues of mice by HPLC with UV-visible detection. Biomed Chromatogr (in press)
14.
go back to reference Codegoni AM, Castagna S, Mangioni C, Scovassi AI, Broggini M, D’Incalci M (1998) DNA-topoisomerase I activity and content in epithelial ovarian cancer. Ann Oncol 9:313–319CrossRefPubMed Codegoni AM, Castagna S, Mangioni C, Scovassi AI, Broggini M, D’Incalci M (1998) DNA-topoisomerase I activity and content in epithelial ovarian cancer. Ann Oncol 9:313–319CrossRefPubMed
15.
go back to reference Sorensen IK, Kristiansen E, Mortensen A, Nicolaisen GM, Wijnandes JAH, van Kranen HJ, van Kreijl CF (1998) The effect of soy isoflavones on the development of intestinal neoplasia in the Apc(Min) mouse. Cancer Lett 130:217–225CrossRefPubMed Sorensen IK, Kristiansen E, Mortensen A, Nicolaisen GM, Wijnandes JAH, van Kranen HJ, van Kreijl CF (1998) The effect of soy isoflavones on the development of intestinal neoplasia in the Apc(Min) mouse. Cancer Lett 130:217–225CrossRefPubMed
16.
go back to reference Mahmoud NN, Carothers AM, Grunberger D, Bilinski RT, Churchill MR, Martucci C, Newmark HL, Bertagnolli MM (2000) Plant phenolics decrease intestinal tumors in an animal model of familial adenomatous polyposis. Carcinogenesis 21:921–927CrossRefPubMed Mahmoud NN, Carothers AM, Grunberger D, Bilinski RT, Churchill MR, Martucci C, Newmark HL, Bertagnolli MM (2000) Plant phenolics decrease intestinal tumors in an animal model of familial adenomatous polyposis. Carcinogenesis 21:921–927CrossRefPubMed
17.
go back to reference Ferry DR, Smith A, Malkhandi J, Fyfe DW, DeTakats GG, Anderson D, Baker J, Kerr DJ (1996) Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res 2:659–668PubMed Ferry DR, Smith A, Malkhandi J, Fyfe DW, DeTakats GG, Anderson D, Baker J, Kerr DJ (1996) Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res 2:659–668PubMed
Metadata
Title
Preliminary safety evaluation of the putative cancer chemopreventive agent tricin, a naturally occurring flavone
Authors
Richard D. Verschoyle
Peter Greaves
Hong Cai
Arndt Borkhardt
Massimo Broggini
Maurizio D’Incalci
Ed Riccio
Rupa Doppalapudi
Izet M. Kapetanovic
William P. Steward
Andreas J. Gescher
Publication date
01-01-2006
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 1/2006
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-005-0039-y

Other articles of this Issue 1/2006

Cancer Chemotherapy and Pharmacology 1/2006 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine